Transcending TransCelerate

Building on its efforts to improve and accelerate clinical trials, TransCelerate BioPharma Inc. has created a subsidiary consortium, BioCelerate, to tackle industry-wide challenges in the preclinical space. However, the new consortium is starting out slower than its parent, with only six members and a single project, limited to sharing tox data, as the partners try to carve out other areas of safe terrain for precompetitive collaboration.

BioCelerate is keeping its finances separate from TransCelerate, but is built with the same not-for-profit model, and is likewise funded by its members: Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline plc, Novo Nordisk A/S and Shionogi & Co. Ltd. Financial details and membership fees haven't been disclosed...